Panagora Asset Management Inc. Buys 58,336 Shares of BioAtla, Inc. (NASDAQ:BCAB)

Panagora Asset Management Inc. lifted its stake in shares of BioAtla, Inc. (NASDAQ:BCAB) by 110.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 111,366 shares of the company’s stock after acquiring an additional 58,336 shares during the quarter. Panagora Asset Management Inc.’s holdings in BioAtla were worth $274,000 at the end of the most recent reporting period.

Separately, Sectoral Asset Management Inc. boosted its holdings in BioAtla by 26.9% in the 3rd quarter. Sectoral Asset Management Inc. now owns 706,062 shares of the company’s stock worth $1,200,000 after buying an additional 149,544 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BCAB shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of BioAtla in a research note on Wednesday, May 15th. JMP Securities decreased their price target on BioAtla from $12.00 to $5.00 and set a “market outperform” rating on the stock in a report on Thursday.

BioAtla Stock Performance

Shares of NASDAQ:BCAB opened at $1.71 on Friday. The firm has a market cap of $82.28 million, a PE ratio of -0.69 and a beta of 1.23. The firm’s 50 day simple moving average is $2.84 and its 200-day simple moving average is $2.42. BioAtla, Inc. has a one year low of $1.24 and a one year high of $4.02.

BioAtla (NASDAQ:BCAB) last issued its earnings results on Tuesday, March 26th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.12. Equities research analysts predict that BioAtla, Inc. will post -1.72 EPS for the current fiscal year.

BioAtla Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.